Research and Development of mAb114 for Ebola

The Department of Health and Human Services, through its Assistant Secretary for Preparedness and Response, awarded a sole source contract to Ridgeback Biotherapeutics LP for the research and development of mAb114, a monoclonal antibody treatment for Ebola. This contract was justified under Federal Acquisition Regulation (FAR) 6.302-1, which permits other than full and open competition when only one responsible source is available and no alternative supplies or services can meet the agency’s requirements. The action aligns with FAR Part 6.305 requirements for documenting and posting a redacted Justification and Approval for this sole source procurement. The contract, identified by solicitation number 75A50120C00009RedactedJA, was posted on March 24, 2020, under the NAICS code 541714, related to research and development in the biosciences. The place of performance is Coconut Grove, Florida, while the contracting office is located in Washington, DC. The point of contact for this contract is Ethan Mueller. This procurement supports the strategic preparedness and response efforts of the Department of Health and Human Services in addressing critical public health threats like Ebola through the development of specialized biotherapeutic treatments.